Nicolas Belmar

ResearcherPublications, citations & collaboration network

Nicolas Belmar is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 22 works, 235 citations, an h-index of 6 and an i10-index of 3.

Works

235

Citations

h-index

i10-index

IDs:OpenAlex

How has Nicolas Belmar's publication output changed over time?

ScholarIQpublication output · 2024–2026

Output declined33% over the shown period — from 3 works in 2024 to 2 in 2026.

202420252026

What are the most-cited papers on Nicolas Belmar?

ScholarIQmost cited works

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

Johannes F.E. Mann, Peter Rossing, George L. Bakris, Nicolas Belmar, Heidrun Bosch‐Traberg, Robert S. Busch, David M. Charytan, Samy Hadjadj, Pieter Gillard, José Luis Górriz, Thomas Idorn, Linong Ji, Kenneth W. Mahaffey, Vlado Perkovic, Søren Rasmussen, Roland E. Schmieder, Richard E. Pratley, Katherine R. Tuttle

Nature Medicine. 2024165 CitationsOPEN ACCESS

Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis

Peter Rossing, George L. Bakris, Vlado Perkovic, Richard E. Pratley, Katherine R. Tuttle, Kenneth W. Mahaffey, Thomas Idorn, Nicolas Belmar, Heidrun Bosch‐Traberg, Søren Rasmussen, Robert S. Busch, Roland E. Schmieder, Pieter Gillard, Johannes F. E. Mann, FLOW Investigator Group, Andrea Da Porto, A. Oviedo, Alicia Elbert, Elizabeth Gelersztein, Alejandro Chertkoff, A. Wassermann, Miguel Ángel Quevedo, R. J. MacIsaac, S Roger, Richard Phoon, Kerr Pg, Andrew E. Ajani, Shaobo Tan, David Colquhoun, Amanda Mather, P. Gillard, Christophe De Block, Corinne Debroye, Francis Duyck, J.M. Krzesinski, Bruno Lapauw, V. Preumont, C. Vercammen, Zdravko Kamenov, Roza Bobeva, G. Levterov, S. Gerilovska, N. Yabrudi, Bilyana Stoyanovska-Elencheva, Z. Nikitov, Daniel Franco, Gustavo Akerman Augusto, Jean‐Pierre Salles, Luís Henrique Santos Canani, Márcio Krakauer, Maria Cerqueira, Miguel C. Riella, Hitasha Bajaj, Rolf Schlößer, Buki Ajala, Neeru P Aggarwal, R Dumas, Daniel J. O’Keefe, Sean Peterson, George Tsoukas, Chetna Tailor, Richard Tytus, Ronald Akhras, Hasnain Khandwala, Oren Steen, Diane Carbonneau, Jihoon Cha, Ann Steele, G. HOWARD BAILEY, Joseph Berlingieri, Peter Dzongowski, David Z.I. Cherney, Thomas G. Elliott, C. J. Kovacs, Pavel Hamet, BRUCE PERKINS, Karthik Tennankore, Anil Kumar Gupta, Linong Ji, Yan Li, Gongsheng Yuan, Xinzhong Dong, B. Cariou, S. Clavel, Loı̈c Le Marchand, Yves Reznik, Philippe Moulin, E. Legrand, I. Benoit Tricaud, Pierre Gourdy, Philippe Zaoui, Anne Monier, Isabelle Kazes, Dominik Dahl, Melissa M. Esser, Thilo Krüger, Ludger Rose, R. Schmieder, Alexander Segner, Young Hee Lee-Barkey

Diabetes Care. 202516 CitationsOPEN ACCESS

Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease

David Z.I. Cherney, Nicolas Belmar, Petter Bjornstad, Milenta Mariam Chacko, Thomas P. Gunnarsson, Jeffrey B. Hodgin, Matthias Kretzler, Menno Pruijm, Philip Andreas Schytz, Katherine R. Tuttle

Nephrology Dialysis Transplantation. 202514 CitationsOPEN ACCESS

Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6

Stephen C. Bain, Nicolas Belmar, Søren T. Hoff, Mansoor Husain, Søren Rasmussen, Tina Vilsbøll, Mark C. Petrie

Diabetes Therapy. 20249 CitationsOPEN ACCESS

REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide

Menno Pruijm, Nicolas Belmar, Petter Bjornstad, David Z.I. Cherney, Vivek Das, Thomas P. Gunnarsson, Jeffrey B. Hodgin, Philip Andreas Schytz, Katherine R. Tuttle, Matthias Kretzler

Kidney International. 20259 CitationsOPEN ACCESS

Related on ScholarIQ

Novo Nordisk (Denmark)

Institution

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

Paper

Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease

Paper

Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6

Paper

REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide

Paper